Ipswich, MA, United States of America

Lisa L Maduzia

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: New England Biolabs, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lisa L Maduzia. Retrieved from https://idiyas.com/inventor/lisa-l-maduzia

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Lisa L Maduzia: Innovator in RNase Inhibitors

Introduction

Lisa L Maduzia is a prominent inventor based in Ipswich, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of RNase inhibitors. Her work has implications for various applications in molecular biology and research.

Latest Patents

Lisa holds a patent for RNase Inhibitors, showcasing her innovative approach to enhancing the stability and efficacy of RNA in laboratory settings. This patent is a testament to her expertise and dedication to advancing scientific research.

Career Highlights

Lisa is currently associated with New England Biolabs, Inc., a leading company in the life sciences sector. Her role at the company allows her to collaborate with other scientists and contribute to groundbreaking research and product development.

Collaborations

[This section has been skipped due to space constraints.]

Conclusion

Lisa L Maduzia's contributions to the field of biotechnology through her patent on RNase inhibitors highlight her role as an influential inventor. Her work continues to impact the scientific community positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…